Method for treating idiopathic pulmonary fibrosis
AssigneeNumedii, Inc.
InventorsAsim Siddiqui, Heather Arnett, Linda De Young, Tarangini Deshpande
Life of this patent
Estimating the term…
Abstract
Provided is a method of treating idiopathic pulmonary fibrosis (IPF) using an agent that reduces or eliminates the kinase activity of checkpoint kinase 1 (Chk1).
Claims21
1-62. (canceled)
A method of treating pulmonary fibrosis in a subject in need thereof, comprising administering to the subject a therapeutically-effective amount of a pharmaceutical composition, wherein the pharmaceutical composition comprises a Chk1 inhibitor, wherein upon the administering, the Chk1 inhibitor reduces a level of fibroblast to myofibroblast differentiation in the subject by at least about 5% relative to a control.
A method of reducing differentiation of a fibroblast into a myofibroblast, comprising contacting a population of cells with a Chk1 inhibitor, wherein the population of cells comprises the fibroblast, wherein upon contacting the population of cells with the Chk1 inhibitor, the fibroblast exhibits an expression level of alpha smooth muscle actin that is at least about 5% lower than an expression level of the alpha smooth muscle actin by a fibroblast that was not contacted with the Chk1 inhibitor.
A method of reducing collagen deposition, comprising contacting a tissue with a Chk1 inhibitor, wherein upon contacting the tissue with the Chk1 inhibitor, the tissue exhibits an at least about 5% lower level of an indicator of collagen deposition relative to a tissue that was not contacted with the Chk1 inhibitor.
Dependencies are inferred from the claim text.